Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Wenfeng Fang's publication output changed over time?
ScholarIQpublication output · 2014–2024
Output grew0% over the shown period — from 1 works in 2014 to 1 in 2024.
1
2
2
2
1
1
1
1
1
201420152016201720182019202120232024
What are the most-cited papers on Wenfeng Fang?
ScholarIQmost cited works
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen, Wenfeng Fang, Jianhua Zhan, Shaodong Hong, Yanna Tang, Shiyang Kang, Yaxiong Zhang, Xiaobo He, Ting Zhou, Tao Qin, Yan Huang, Xianping Yi, Li Zhang
Journal of Thoracic Oncology. 2015689 CitationsOPEN ACCESS
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang
The Lancet Oncology. 2018508 Citations
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, G. Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Lei Feng, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiao‐Jing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang
The Lancet Oncology. 2021461 Citations
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou, Xuan Wu, Wenhua Liang, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yue Yan, Xue Hou, Pei-Yu Huang, Yan Huang, Hongyun Zhao, Li Zhang
Oncotarget. 2014392 CitationsOPEN ACCESS
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen, Wenfeng Fang, Lin Zhong, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Sheng Jin, Ting Zhou, Ying Chen, Hongyu Zhang, Li Zhang
S203303425. 2017294 CitationsOPEN ACCESS
Related on ScholarIQ
Sun Yat-sen University
Institution
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Paper
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Paper
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Paper
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Paper
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Paper